230 related articles for article (PubMed ID: 29620483)
1. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
Misenko SM; Patel DS; Her J; Bunting SF
Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
[TBL] [Abstract][Full Text] [Related]
2. BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA double-strand break sites.
Patel DS; Misenko SM; Her J; Bunting SF
J Cell Biol; 2017 Nov; 216(11):3521-3534. PubMed ID: 28912125
[TBL] [Abstract][Full Text] [Related]
3. Defining and Modulating 'BRCAness'.
Byrum AK; Vindigni A; Mosammaparast N
Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
[TBL] [Abstract][Full Text] [Related]
4. CtIP-mediated resection is essential for viability and can operate independently of BRCA1.
Polato F; Callen E; Wong N; Faryabi R; Bunting S; Chen HT; Kozak M; Kruhlak MJ; Reczek CR; Lee WH; Ludwig T; Baer R; Feigenbaum L; Jackson S; Nussenzweig A
J Exp Med; 2014 Jun; 211(6):1027-36. PubMed ID: 24842372
[TBL] [Abstract][Full Text] [Related]
5. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
Chen J; Li P; Song L; Bai L; Huen MSY; Liu Y; Lu LY
Cell Death Differ; 2020 Sep; 27(9):2552-2567. PubMed ID: 32139898
[TBL] [Abstract][Full Text] [Related]
7. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok C; Kok YP; van den Tempel N; van Vugt MATM
Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
[TBL] [Abstract][Full Text] [Related]
8. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
Becker JR; Cuella-Martin R; Barazas M; Liu R; Oliveira C; Oliver AW; Bilham K; Holt AB; Blackford AN; Heierhorst J; Jonkers J; Rottenberg S; Chapman JR
Nat Commun; 2018 Dec; 9(1):5406. PubMed ID: 30559443
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
10. EXO1 protects BRCA1-deficient cells against toxic DNA lesions.
van de Kooij B; Schreuder A; Pavani R; Garzero V; Uruci S; Wendel TJ; van Hoeck A; San Martin Alonso M; Everts M; Koerse D; Callen E; Boom J; Mei H; Cuppen E; Luijsterburg MS; van Vugt MATM; Nussenzweig A; van Attikum H; Noordermeer SM
Mol Cell; 2024 Feb; 84(4):659-674.e7. PubMed ID: 38266640
[TBL] [Abstract][Full Text] [Related]
11. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
[TBL] [Abstract][Full Text] [Related]
12. Bloom DNA helicase facilitates homologous recombination between diverged homologous sequences.
Kikuchi K; Abdel-Aziz HI; Taniguchi Y; Yamazoe M; Takeda S; Hirota K
J Biol Chem; 2009 Sep; 284(39):26360-7. PubMed ID: 19661064
[TBL] [Abstract][Full Text] [Related]
13. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching.
Bothmer A; Rommel PC; Gazumyan A; Polato F; Reczek CR; Muellenbeck MF; Schaetzlein S; Edelmann W; Chen PL; Brosh RM; Casellas R; Ludwig T; Baer R; Nussenzweig A; Nussenzweig MC; Robbiani DF
J Exp Med; 2013 Jan; 210(1):115-23. PubMed ID: 23254285
[TBL] [Abstract][Full Text] [Related]
15. A Novel Mechanism to Induce BRCAness in Cancer Cells.
Cai C
Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
[TBL] [Abstract][Full Text] [Related]
16. ZMYM2 restricts 53BP1 at DNA double-strand breaks to favor BRCA1 loading and homologous recombination.
Lee D; Apelt K; Lee SO; Chan HR; Luijsterburg MS; Leung JWC; Miller KM
Nucleic Acids Res; 2022 Apr; 50(7):3922-3943. PubMed ID: 35253893
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
Zimmer J; Tacconi EMC; Folio C; Badie S; Porru M; Klare K; Tumiati M; Markkanen E; Halder S; Ryan A; Jackson SP; Ramadan K; Kuznetsov SG; Biroccio A; Sale JE; Tarsounas M
Mol Cell; 2016 Feb; 61(3):449-460. PubMed ID: 26748828
[TBL] [Abstract][Full Text] [Related]
18. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
19. Super-resolution mapping of cellular double-strand break resection complexes during homologous recombination.
Whelan DR; Rothenberg E
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33707212
[TBL] [Abstract][Full Text] [Related]
20. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
